Although GLS1 protein levels remained unchanged following palbociclib treatment (Figure S4a), intracellular glutamate levels were significantly increased in both cell lines (Figure 3a), indicating increased glutamine pathway activity and a potential role for glutamine metabolism in mitochondrial reprogramming following CDK4/6 inhibition in melanoma cells. The gene discussed is CDK4; the disease is melanoma.